Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
John Kuruvilla(Princess Margaret Cancer Centre), Nancy L. Bartlett(Washington University in St. Louis), Mehdi Hamadani(Medical College of Wisconsin), Joshua Brody(New York University), Mohammed Z.H. Farooqui(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alex F. Herrera(City of Hope), Vincent Ribrag(Institut Gustave Roussy), Patricia Marinello(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jacob D. Bitran(Advocate Lutheran General Hospital), Franck Morschhauser(Hôpital Claude Huriez), David Avigan(Beth Israel Deaconess Medical Center), Philippe Armand(Harvard University), Abraham S. Kanate(HonorHealth), Hervé Ghesquières(Université Claude Bernard Lyon 1), Stephen J. Schuster(Hospital of the University of Pennsylvania), Craig H. Moskowitz(University of Miami), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Justin Kline(University of Chicago)
Cited by 28
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k